uprevstobart
Generic: Uprevstobart
uprevstobart: 1 clinical trial tracked.
uprevstobart evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about uprevstobart, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Primary endpoint: Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEs
Interventionalopen57 targetStarted 2021-10Completion 2024-0932 sites · Austria, Belgium, Netherlands, Spain…Incyte Corporation